Engineered anti-TGF-beta antibodies and antigen-binding fragments

US9783604B2 · kind B2 · utility

Assignee

• Genzyme Corporation · US

Inventors

• Ronnie Wei · Weston, US
• Aaron Moulin · Ashland, US
• Magali Mathieu · Choisy-le-Roi, FR
• Clark Pan · Sudbury, US
• Sunghae Park · Bound Brook, US
• Huawei Qiu · Westborough, US

Key dates

• Filing date: Mar 11, 2014
• Grant date: Oct 10, 2017
• Expiry date: Mar 11, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.